2,030 results on '"Moschini, Marco"'
Search Results
152. Psychological Health of Surgeons in a Time of COVID-19: A Global Survey
153. Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival
154. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer
155. Prognostic Value of Serum Cholinesterase in Non–muscle-invasive Bladder Cancer
156. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis.
157. Perioperative and oncological outcomes of distal ureter management during nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis.
158. Repeat Transurethral Resection for Non–muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era
159. Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer
160. Organ-sparing treatment for T1 and T2 penile cancer: an updated literature review
161. Re: A Randomized Trial of PHOTOdynamic Surgery in Non–muscle-invasive Bladder Cancer
162. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs
163. Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy
164. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies
165. Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy
166. Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer
167. Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer
168. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study
169. The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer
170. Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy
171. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study
172. Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study
173. Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma
174. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis
175. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non–muscle-invasive Bladder Cancer
176. Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy
177. Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients
178. Oncological and safety profiles in patients undergoing simultaneous <scp>transurethral resection (TUR) of bladder tumour</scp> and <scp>TUR of the prostate</scp>
179. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy
180. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Letter.
181. LBA03-12 BIOLOGY AND PERFORMANCE OF PRE- AND POST-PEMBROLIZUMAB (PEMBRO) VESICAL IMAGING-REPORTING AND DATA SYSTEM (VI-RADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): FULL DATA ANALYSIS FROM A CLINICAL TRIALS PIPELINE
182. Data from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
183. Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505–16
184. Supplementary Table S3 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
185. MP67-06 OUTCOMES OF PROSTATE CANCER PATIENTS WITH SEMINAL VESICLE INVASION AT MULTIPARAMETRIC MRI MANAGED WITH RADICAL PROSTATECTOMY. DO ALL PATIENTS REALLY NEED A MULTI-MODAL APPROACH?
186. MP40-07 HAS THE INTRODUCTION OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE AND TARGETED BIOPSIES LED TO A RISK OF OVERGRADING OF HIGH RISK PROSTATE CANCER? RESULTS FROM A CONTEMPORARY LARGE MULTI-INSTITUTIONAL SERIES.
187. PD46-06 UROLOGICAL FOLLOW-UP AND MUTATIONAL PATTERNS IN LYNCH SYNDROME PATIENTS: A SINGLE CENTER EXPERIENCE
188. MP63-19 ADEQUATE VS INADEQUATE BCG INTRAVESICAL THERAPY IN INTERMEDIATE AND HIGH RISK NMIBC: TOTAL NUMBER OF INSTILLATIONS IS WHAT REALLY MATTERS
189. MP46-08 DIAGNOSTIC PERFORMANCE OF PET-CT COMPARED TO CONVENTIONAL CT FOR LYMPH NODE STAGING IN BLADDER CANCER PATIENTS UNDERGOING RADICAL CYSTECTOMY AND BILATERAL PELVIC LYMPH NODE DISSECTION
190. PD44-06 CHEMOTHERAPY VS IMMUNOTHERAPY AS NEOADJUVANT THERAPIES IN CISPLATIN-ELIGIBLE PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER
191. MP32-16 FUNCTIONAL OUTCOMES IN FEMALE PATIENTS AFTER TRADITIONAL, ORGAN- AND NERVE-SPARING RADICAL CYSTECTOMY AND URINARY DIVERSION FOR BLADDER CANCER: A SYSTEMATIC REVIEW AND POOLED ANALYSES
192. Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
193. PD39-04 MPMRI OF THE PROSTATE IN PATIENTS CARRYING A HIGH CLINICAL RISK OF PROSTATE CANCER DIAGNOSIS: IS THIS IMAGING TEST NECESSARY FOR DIAGNOSTIC PURPOSES IN THIS SUBSET OF PATIENTS?
194. PD09-04 PREDICTION OF 90-DAY MORTALITY AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER IN LARGE-SCALE MULTICENTER COLLABORATION STUDY
195. MP46-19 THE ROLE OF EXTENDED VERSUS STANDARD LYMPHADENECTOMY LYMPH NODE DISSECTION IN CLINICALLY LYMPH NODE-POSITIVE BLADDER CANCER
196. PD13-09 CLINICAL VALIDATION OF THE EAU2021 INTERMEDIATE RISK NMIBC DEFINITION AND IMPLICATIONS FOR ADJUVANT TREATMENT: A MULTICENTER YAU UROTHELIAL COLLABORATION
197. PD39-06 INTEGRATING INDEX LESION VOLUME TO BETTER CLASSIFY MEN WITH INDOLENT PROSTATE CANCER AMONG PATIENTS WITH INTERMEDIATE RISK DISEASE. RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES
198. MP08-14 LONG TERM OUTCOMES OF REPEATED MITOMYCIN C INSTILLATION IN LOW RISK AND INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
199. PD36-04 UTILITY OF PRE- AND POST-PEMBROLIZUMAB VESICAL IMAGING – REPORTING AND DATA SYSTEM (VIRADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): AN ANALYSIS OF THE PURE-01 COHORT
200. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.